Shekaru ashirin da suka wuce, an ba da albendazole ga wani babban shiri don maganin filariasis na lymphatic. Wani bita na Cochrane na baya-bayan nan yayi nazarin ingancin albendazole a cikin maganin filariasis na lymphatic.
Lymphatic filariasis cuta ce ta gama-gari a yankuna masu zafi da na wurare masu zafi, waɗanda sauro ke yaɗuwa da kamuwa da cutar filariasis na parasitic. Bayan kamuwa da cuta, larvae suna girma zuwa manya da ma'aurata don samar da microfilariae (MF). Sai sauro ya ɗauki MF yayin da yake ciyar da jini, kuma cutar za a iya kaiwa ga wani mutum.
Ana iya gano kamuwa da cuta ta hanyar gwaji don kewaya MF (microfilamentemia) ko antigens parasites (antigenemia) ko ta hanyar gano tsutsotsi masu girma ta hanyar ultrasonography.
Hukumar Lafiya ta Duniya (WHO) ta ba da shawarar a rika yi wa daukacin al’ummar kasar magani a kowace shekara har na tsawon akalla shekaru biyar. Tushen jiyya shine haɗuwa da kwayoyi guda biyu: albendazole da microfilaricidal (antifilariasis) miyagun ƙwayoyi diethylcarmazine (DEC) ko ivermectin.
Albendazole kadai ana ba da shawarar don amfani na shekara-shekara a wuraren da cutar Roa ke da alaƙa, inda bai kamata a yi amfani da DEC ko ivermectin ba saboda haɗarin haɗari mai haɗari.
Dukansu ivermectin da DEC sun kawar da kamuwa da MF da sauri kuma sun danne maimaitawarsa. Duk da haka, samar da MF zai ci gaba saboda ƙarancin bayyanarwa a cikin manya. An yi la'akari da Albendazole don maganin filariasis na lymphatic bayan wani bincike ya nuna cewa yawan allurai da aka yi a cikin makonni da yawa ya haifar da mummunar illa da ke nuna mutuwar tsofaffin tsutsotsi.
Wani shawarwari na WHO na yau da kullun daga baya ya nuna cewa albendazole yana da aikin kashewa ko haifuwa ga tsutsotsi na manya. A shekara ta 2000, GlaxoSmithKline ya fara ba da gudummawar albendazole ga ayyukan da za a magance filariasis na lymphatic.
Gwajin gwaje-gwajen da aka bazu (RCTs) sun bincika inganci da amincin albendazole kadai ko a hade tare da ivermectin ko DEC. Daga baya, an yi bita na tsari da yawa na gwaje-gwajen da aka sarrafa bazuwar da bayanan lura, amma ba a sani ba ko albendazole yana da wani fa'ida a cikin filariasis na lymphatic.
Dangane da wannan, an sabunta nazarin Cochrane da aka buga a cikin 2005 don tantance tasirin albendazole akan marasa lafiya da al'ummomin da ke da filariasis na lymphatic.
Bita na Cochrane nazari ne na tsari wanda ke nufin ganowa, kimantawa, da kuma taƙaita duk hujjojin da suka dace da ƙayyadaddun sharuɗɗan don amsa tambayar bincike. An sabunta sake dubawa na Cochrane yayin da sabbin bayanai suka samu.
Hanyar Cochrane tana rage son zuciya a cikin tsarin bita. Wannan ya haɗa da yin amfani da kayan aiki don tantance haɗarin rashin son zuciya a cikin gwaje-gwajen mutum ɗaya da kuma tantance tabbacin (ko inganci) na shaidar kowane sakamako.
An sabunta Sharhin Cochrane "Albendazole kadai ko a hade tare da wakilai na microfilaricidal a cikin filariasis lymphatic" a cikin Janairu 2019 ta Cochrane Cututtukan Cututtuka da COUNTDOWN Consortium.
Sakamakon sha'awa sun haɗa da yuwuwar watsawa (yawan MF da yawa), alamomin kamuwa da tsutsotsi na manya (yawan cutar antigenemia da yawa, da gano duban dan tayi na tsofaffin tsutsotsi), da ma'auni na abubuwan da ba su dace ba.
Marubutan sun yi ƙoƙarin yin amfani da binciken lantarki don nemo duk gwajin da ya dace har zuwa Janairu 2018, ba tare da la’akari da harshe ko matsayin ɗaba'a ba. Mawallafa biyu sun tantance karatun da kansu don haɗawa, kimanta haɗarin son zuciya, da fitar da bayanan gwaji.
Binciken ya ƙunshi gwaji 13 tare da jimlar mahalarta 8713. An yi nazari kan yawaitar ƙwayoyin cuta da kuma illa don auna tasirin jiyya. Shirya teburi don yin nazarin sakamakon ƙarancin ƙwayar cuta, saboda ƙarancin rahoto yana nufin ba za a iya haɗa bayanai ba.
Mawallafa sun gano cewa albendazole kadai ko a hade tare da microfilaricides ba su da wani tasiri a kan yawan MF tsakanin makonni biyu da watanni 12 bayan jiyya (shaida mai inganci).
Ba su sani ba ko akwai tasiri akan girman mf a cikin watanni 1-6 (shaida mara ƙarancin inganci) ko kuma a cikin watanni 12 (shaida mara ƙarancin inganci).
Albendazole kadai ko a hade tare da microfilaricides ba su da wani tasiri a kan yaduwar antigenemia a kan watanni 6-12 (shaida mai inganci).
Marubutan ba su sani ba idan akwai tasiri akan yawan antigen tsakanin watanni 6 da 12 (shaida maras inganci). Albendazole da aka ƙara zuwa microfilaricides mai yiwuwa ba shi da wani tasiri a kan yawaitar tsutsotsi na manya da aka gano ta hanyar duban dan tayi a watanni 12 (shaida maras tabbas).
Lokacin amfani da shi kadai ko a hade, albendazole ba shi da wani tasiri a kan adadin mutanen da ke ba da rahoto mara kyau (shaida mai inganci).
Binciken ya sami isasshiyar shaida cewa albendazole, kadai ko a hade tare da microfilaricides, ba shi da wani tasiri ko rashin tasiri akan cikakken kawar da microfilariae ko helminths manya a cikin watanni 12 na jiyya.
Ganin cewa wannan magani wani bangare ne na manufofin al'ada, kuma Hukumar Lafiya ta Duniya a yanzu kuma ta ba da shawarar tsarin magunguna uku, da wuya masu bincike su ci gaba da tantance albendazole tare da DEC ko ivermectin.
Koyaya, a cikin wuraren da ke fama da cutar Roa, albendazole ne kawai ake ba da shawarar. Saboda haka, fahimtar ko maganin yana aiki a cikin waɗannan al'ummomin ya kasance babban fifikon bincike.
Manyan ƙwayoyin kwari na filariatic tare da jadawalin aikace-aikacen ɗan gajeren lokaci na iya yin babban tasiri akan shirye-shiryen kawar da filariasis. Ɗaya daga cikin waɗannan magungunan a halin yanzu yana cikin ci gaba na asali kuma an buga shi a cikin BugBitten blog na kwanan nan.
Ta ci gaba da amfani da wannan rukunin yanar gizon, kun yarda da Sharuɗɗan Amfani, Sharuɗɗan Al'umma, Bayanin Keɓaɓɓen Sirri da Manufar Kuki.